제약바이오산업의 이슈와 지속가능경영

This study examined the sustainable management of the biopharmaceutical industry, which is emerging as a key growth industry for the future of Korea. By exploring literature and expert opinions, we identified 14 major issues facing the industry and analyzed how these issues were addressed in the sustainability reports publicly published by the top 4 companies based on sales. As a result of the analysis, first, 14 issues are dealt with in-depth in four reports, so it is considered that the overall efforts of the biopharmaceutical industry for sustainable management are active. Second, although greenhouse gas emissions are recorded and disclosed, data on carbon neutrality and greenhouse gas reduction efforts were insufficient. Third, there is a principle for minimizing animal experiments, but specific data are insufficient. Fourth, the composition of the board of directors has not been advanced. Fifth, there was a lack of awareness and effort on digital transformation. As a limitation of this study, the contents of the company's sustainability management report were not confirmed because the company's sustainability management report was analyzed. In addition, the issues presented in this study are not absolute standards for sustainable management. However, by looking at how companies are responding to major issues that are emerging as major concerns at the present time, it can help improve awareness and urge them to come up with countermeasures for improvement.